Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - Jefferies initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a Buy rating and a $43.00 price target on Friday. The stock currently trades at $26.09, with analyst targets ranging from $6 to $54, reflecting mixed sentiment despite a strong consensus Buy recommendation.
The research firm’s coverage follows Liquidia’s FDA approval of Yutrepia, a dry powder inhaled treprostinil therapy, on May 23, 2025, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Liquidia stock has gained approximately 75% from June through the first reported quarter of Yutrepia revenues, according to Jefferies.
The firm acknowledged two major challenges facing Liquidia: an ongoing five-year patent battle with United Therapeutics over Yutrepia, and upcoming competition from Insmed’s once-daily inhaled treprostinil, which is expected to enter Phase 3 trials between the second half of 2025 and first half of 2026.
At a $2.2 billion market capitalization, Jefferies believes the current stock price already accounts for most negative factors, including minimal market penetration in PAH/PH-ILD and mid-teens percentage royalties in PH-ILD, while assigning no value to the company’s pipeline.
In other recent news, Liquidia Technologies reported its second-quarter earnings for 2025, showcasing a significant revenue increase. The company achieved $8.8 million in revenue, far exceeding the forecast of $3.92 million, largely due to strong sales of its Yutrepia product. Despite a larger-than-expected loss per share of $0.49, compared to the forecasted $0.42, analysts have maintained a positive outlook on the company’s performance. BTIG raised its price target for Liquidia to $49 from $40, maintaining a Buy rating, citing stronger-than-expected patient adoption of Yutrepia. Raymond James also increased its price target to $41 from $33, maintaining a Strong Buy rating, following the company’s earnings report. Wells Fargo raised its price target to $31 from $25, maintaining an Overweight rating, due to the robust launch performance of Yutrepia. These developments highlight the positive reception and adoption of Liquidia’s product in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.